Details of the Drug

General Information of Drug (ID: DMXLKHV)

• Drug Name: Oxycodone

Indication

Disease Entry	ICD 11	Status	REF
Osteoarthritis	FA00-FA05	Approved	[1]
Pain	MG30-MG3Z	Approved	[2]
Back pain	ME84.Z	Phase 3	[3]

• Therapeutic Class: Analgesics
• Affected Organisms: Humans and other mammals
• ATC Code:
  N02AA05: Oxycodone
  N02AA: Natural opium alkaloids
  N02A: OPIOIDS
  N02: ANALGESICS
  N: NERVOUS SYSTEM
  N02AA05: Oxycodone
  N02AA: Natural opium alkaloids
  N02A: OPIOIDS
  N02: ANALGESICS
  N: NERVOUS SYSTEM
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 315.4
  Logarithm of the Partition Coefficient (xlogp); 1.2
  Rotatable Bond Count (rotbonds); 1
  Hydrogen Bond Donor Count (hbonddonor); 1
  Hydrogen Bond Acceptor Count (hbondacc); 5
• ADMET Property:
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
  Clearance: The total plasma clearance of drug is 1.4 L/min []
  Elimination: 19% of drug is excreted from urine in the unchanged form [4]
  Half-life: The concentration or amount of drug in body reduced by one-half in 3.2 hours [5]
  Metabolism: The drug is metabolized via the hepatic [5]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 1.05589 micromolar/kg/day [6]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.55% [7]
  Vd: The volume of distribution (Vd) of drug is 2.6 L/kg []
  Water Solubility: The ability of drug to dissolve in water is measured as 100 mg/mL [4]
• Chemical Identifiers:
  Formula: C18H21NO4
  IUPAC Name: (4R,4aS,7aR,12bS)-4a-hydroxy-9-methoxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one
  Canonical SMILES: CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)OC)O4)O
  InChI: InChI=1S/C18H21NO4/c1-19-8-7-17-14-10-3-4-12(22-2)15(14)23-16(17)11(20)5-6-18(17,21)13(19)9-10/h3-4,13,16,21H,5-9H2,1-2H3/t13-,16+,17+,18-/m1/s1
  InChIKey: BRUQQQPBMZOVGD-XFKAJCMBSA-N
• Cross-matching ID:
  PubChem CID: 5284603
  ChEBI ID: CHEBI:7852
  CAS Number: 76-42-6
  UNII: CD35PMG570
  DrugBank ID: DB00497
  TTD ID: D03SKD
  VARIDT ID: DR00392
  ACDINA ID: D00502
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Opioid receptor delta (OPRD1)	TT27RFC	OPRD_HUMAN	Agonist	[8]
Opioid receptor mu (MOP)	TTKWM86	OPRM_HUMAN	Modulator	[9]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Cyclic AMP-dependent transcription factor ATF-4 (ATF4)	OTRFV19J	ATF4_HUMAN	Gene/Protein Processing	[10]
Cytochrome P450 2D6 (CYP2D6)	OTZJC802	CP2D6_HUMAN	Drug Response	[11]
Cytochrome P450 3A4 (CYP3A4)	OTQGYY83	CP3A4_HUMAN	Regulation of Drug Effects	[12]
Endoplasmic reticulum chaperone BiP (HSPA5)	OTFUIRAO	BIP_HUMAN	Gene/Protein Processing	[10]
Eukaryotic translation initiation factor 2 subunit 1 (EIF2S1)	OTM0GDTP	IF2A_HUMAN	Post-Translational Modifications	[10]

Molecular Expression Atlas of This Drug

• The Studied Disease: Osteoarthritis
• ICD Disease Classification: FA00-FA05

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Opioid receptor mu (MOP)	DTT	OPRM1	5.94E-01	-0.02	-0.17
Opioid receptor delta (OPRD1)	DTT	OPRD1	5.52E-01	0.03	0.23

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Oxycodone

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Pentazocine	DM1XBHS	Major	Additive hypotensive effects by the combination of Oxycodone and Pentazocine.	Pain [MG30-MG3Z]	[13]
Dextropropoxyphene	DM23HCX	Major	Additive CNS depression effects by the combination of Oxycodone and Dextropropoxyphene.	Pain [MG30-MG3Z]	[14]
Butorphanol	DM5KYPJ	Major	Additive hypotensive effects by the combination of Oxycodone and Butorphanol.	Pain [MG30-MG3Z]	[13]
Oxymorphone	DM65AGJ	Major	Additive CNS depression effects by the combination of Oxycodone and Oxymorphone.	Pain [MG30-MG3Z]	[15]
Levorphanol	DMGS80V	Major	Additive CNS depression effects by the combination of Oxycodone and Levorphanol.	Pain [MG30-MG3Z]	[15]
Dezocine	DMJDB0Y	Major	Additive hypotensive effects by the combination of Oxycodone and Dezocine.	Pain [MG30-MG3Z]	[13]
Flavoxate	DMKV4NL	Moderate	Additive antimotility effects by the combination of Oxycodone and Flavoxate.	Pain [MG30-MG3Z]	[16]
Nalbuphine	DMOSQGU	Major	Additive CNS depression effects by the combination of Oxycodone and Nalbuphine.	Pain [MG30-MG3Z]	[13]
Buprenorphine	DMPRI8G	Major	Additive CNS depression effects by the combination of Oxycodone and Buprenorphine.	Pain [MG30-MG3Z]	[13]
Hydrocodone	DMQ2JO5	Major	Additive CNS depression effects by the combination of Oxycodone and Hydrocodone.	Pain [MG30-MG3Z]	[15]

Coadministration of a Drug Treating the Disease Different from Oxycodone (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Metreleptin	DM1NOEK	Moderate	Increased metabolism of Oxycodone caused by Metreleptin mediated induction of CYP450 enzyme.	Acute diabete complication [5A2Y]	[17]
Ivosidenib	DM8S6T7	Major	Increased metabolism of Oxycodone caused by Ivosidenib mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[18]
Arn-509	DMT81LZ	Major	Increased metabolism of Oxycodone caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[18]
Emapalumab	DMZG5WL	Moderate	Altered metabolism of Oxycodone due to Emapalumab alters the formation of CYP450 enzymes.	Adaptive immunity immunodeficiency [4A01]	[19]
Scopolamine	DMOM8AL	Moderate	Additive CNS depression effects by the combination of Oxycodone and Scopolamine.	Addictive disorder [6C50-6C5Z]	[16]
Mitotane	DMU1GX0	Major	Increased metabolism of Oxycodone caused by Mitotane mediated induction of CYP450 enzyme.	Adrenal cancer [2D11]	[18]
Siltuximab	DMGEATB	Moderate	Altered metabolism of Oxycodone due to Siltuximab alters the formation of CYP450 enzymes.	Anemia [3A00-3A9Z]	[19]
Dronedarone	DMA8FS5	Major	Decreased metabolism of Oxycodone caused by Dronedarone mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[20]
Clorazepate	DMC3JST	Major	Additive CNS depression effects by the combination of Oxycodone and Clorazepate.	Anxiety disorder [6B00-6B0Z]	[21]
Methylphenobarbital	DMDSWAG	Major	Increased metabolism of Oxycodone caused by Methylphenobarbital mediated induction of CYP450 enzyme.	Anxiety disorder [6B00-6B0Z]	[22]
Hydroxyzine	DMF8Y74	Major	Additive CNS depression effects by the combination of Oxycodone and Hydroxyzine.	Anxiety disorder [6B00-6B0Z]	[15]
Halazepam	DMPFWO6	Major	Additive CNS depression effects by the combination of Oxycodone and Halazepam.	Anxiety disorder [6B00-6B0Z]	[15]
Chlormezanone	DMTWUXR	Major	Additive CNS depression effects by the combination of Oxycodone and Chlormezanone.	Anxiety disorder [6B00-6B0Z]	[15]
Oxazepam	DMXNZM4	Major	Additive CNS depression effects by the combination of Oxycodone and Oxazepam.	Anxiety disorder [6B00-6B0Z]	[15]
Voriconazole	DMAOL2S	Major	Decreased metabolism of Oxycodone caused by Voriconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[20]
Posaconazole	DMUL5EW	Major	Decreased metabolism of Oxycodone caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[20]
Zafirlukast	DMHNQOG	Moderate	Decreased metabolism of Oxycodone caused by Zafirlukast mediated inhibition of CYP450 enzyme.	Asthma [CA23]	[20]
Desipramine	DMT2FDC	Moderate	Additive serotonergic effects by the combination of Oxycodone and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[23]
Oritavancin	DM28D05	Moderate	Increased metabolism of Oxycodone caused by Oritavancin mediated induction of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[17]
Ciprofloxacin XR	DM2NLS9	Major	Decreased metabolism of Oxycodone caused by Ciprofloxacin XR mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[20]
Dalfopristin	DM4LTKV	Major	Decreased metabolism of Oxycodone caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[20]
Clarithromycin	DM4M1SG	Major	Decreased metabolism of Oxycodone caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[20]
Troleandomycin	DMUZNIG	Major	Decreased metabolism of Oxycodone caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[20]
Telithromycin	DMZ4P3A	Major	Decreased metabolism of Oxycodone caused by Telithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[20]
Cariprazine	DMJYDVK	Major	Additive CNS depression effects by the combination of Oxycodone and Cariprazine.	Bipolar disorder [6A60]	[15]
Erdafitinib	DMI782S	Moderate	Increased metabolism of Oxycodone caused by Erdafitinib mediated induction of CYP450 enzyme.	Bladder cancer [2C94]	[24]
Loperamide	DMOJZQ9	Moderate	Additive CNS depression effects by the combination of Oxycodone and Loperamide.	Bowel habit change [ME05]	[19]
Lapatinib	DM3BH1Y	Moderate	Decreased metabolism of Oxycodone caused by Lapatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[20]
Tucatinib	DMBESUA	Major	Decreased metabolism of Oxycodone caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[20]
Palbociclib	DMD7L94	Moderate	Decreased metabolism of Oxycodone caused by Palbociclib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[20]
Phenylbutazone	DMAYL0T	Moderate	Increased metabolism of Oxycodone caused by Phenylbutazone mediated induction of CYP450 enzyme.	Chronic pain [MG30]	[17]
Dihydrocodeine	DMB0FWL	Major	Additive CNS depression effects by the combination of Oxycodone and Dihydrocodeine.	Chronic pain [MG30]	[21]
Levomilnacipran	DMV26S8	Moderate	Additive serotonergic effects by the combination of Oxycodone and Levomilnacipran.	Chronic pain [MG30]	[23]
Olopatadine	DMKMWQG	Moderate	Additive CNS depression effects by the combination of Oxycodone and Olopatadine.	Conjunctiva disorder [9A60]	[25]
Propofol	DMB4OLE	Moderate	Additive CNS depression effects by the combination of Oxycodone and Propofol.	Corneal disease [9A76-9A78]	[26]
Dextromethorphan	DMUDJZM	Moderate	Additive serotonergic effects by the combination of Oxycodone and Dextromethorphan.	Cough [MD12]	[23]
Mifepristone	DMGZQEF	Major	Decreased metabolism of Oxycodone caused by Mifepristone mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[20]
Pasireotide	DMHM7JS	Moderate	Decreased metabolism of Oxycodone caused by Pasireotide mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[20]
Osilodrostat	DMIJC9X	Moderate	Decreased metabolism of Oxycodone caused by Osilodrostat mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[20]
Lumacaftor	DMCLWDJ	Major	Increased metabolism of Oxycodone caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[27]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Oxycodone caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[20]
Ethanol	DMDRQZU	Moderate	Additive CNS depression effects by the combination of Oxycodone and Ethanol.	Cystitis [GC00]	[28]
MK-8228	DMOB58Q	Major	Decreased metabolism of Oxycodone caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[20]
Aprepitant	DM053KT	Major	Decreased metabolism of Oxycodone caused by Aprepitant mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[20]
Sertraline	DM0FB1J	Moderate	Additive serotonergic effects by the combination of Oxycodone and Sertraline.	Depression [6A70-6A7Z]	[23]
Trimipramine	DM1SC8M	Moderate	Additive serotonergic effects by the combination of Oxycodone and Trimipramine.	Depression [6A70-6A7Z]	[23]
Cyclobenzaprine	DM1YBRM	Major	Additive CNS depression effects by the combination of Oxycodone and Cyclobenzaprine.	Depression [6A70-6A7Z]	[15]
Nortriptyline	DM4KDYJ	Moderate	Additive serotonergic effects by the combination of Oxycodone and Nortriptyline.	Depression [6A70-6A7Z]	[23]
Nefazodone	DM4ZS8M	Major	Decreased metabolism of Oxycodone caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[20]
Paroxetine	DM5PVQE	Moderate	Additive serotonergic effects by the combination of Oxycodone and Paroxetine.	Depression [6A70-6A7Z]	[23]
Vortioxetine	DM6F1PU	Moderate	Additive serotonergic effects by the combination of Oxycodone and Vortioxetine.	Depression [6A70-6A7Z]	[23]
Milnacipran	DMBFE74	Moderate	Additive serotonergic effects by the combination of Oxycodone and Milnacipran.	Depression [6A70-6A7Z]	[23]
Escitalopram	DMFK9HG	Moderate	Additive serotonergic effects by the combination of Oxycodone and Escitalopram.	Depression [6A70-6A7Z]	[23]
Desvenlafaxine	DMHD4PE	Moderate	Additive serotonergic effects by the combination of Oxycodone and Desvenlafaxine.	Depression [6A70-6A7Z]	[23]
OPC-34712	DMHG57U	Major	Additive CNS depression effects by the combination of Oxycodone and OPC-34712.	Depression [6A70-6A7Z]	[15]
Clomipramine	DMINRKW	Moderate	Additive serotonergic effects by the combination of Oxycodone and Clomipramine.	Depression [6A70-6A7Z]	[23]
Trazodone	DMK1GBJ	Moderate	Additive serotonergic effects by the combination of Oxycodone and Trazodone.	Depression [6A70-6A7Z]	[23]
Amoxapine	DMKITQE	Moderate	Additive serotonergic effects by the combination of Oxycodone and Amoxapine.	Depression [6A70-6A7Z]	[23]
Doxepin	DMPI98T	Moderate	Additive serotonergic effects by the combination of Oxycodone and Doxepin.	Depression [6A70-6A7Z]	[23]
Maprotiline	DMPWB7T	Moderate	Additive serotonergic effects by the combination of Oxycodone and Maprotiline.	Depression [6A70-6A7Z]	[23]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Oxycodone and Esketamine.	Depression [6A70-6A7Z]	[20]
Mepenzolate	DM8YU2F	Moderate	Additive CNS depression effects by the combination of Oxycodone and Mepenzolate.	Digestive system disease [DE2Z]	[16]
5-hydroxy-L-tryptophan	DMDWZGJ	Moderate	Additive serotonergic effects by the combination of Oxycodone and 5-hydroxy-L-tryptophan.	Discovery agent [N.A.]	[23]
Oxybutynine	DMJPBAX	Moderate	Additive CNS depression effects by the combination of Oxycodone and Oxybutynine.	Discovery agent [N.A.]	[16]
Heroin diacetylmorphine	DMDBWHY	Major	Additive CNS depression effects by the combination of Oxycodone and Heroin diacetylmorphine.	Dissociative neurological symptom disorder [6B60]	[21]
Fenfluramine	DM0762O	Moderate	Additive serotonergic effects by the combination of Oxycodone and Fenfluramine.	Epilepsy/seizure [8A61-8A6Z]	[23]
Primidone	DM0WX6I	Major	Additive CNS depression effects by the combination of Oxycodone and Primidone.	Epilepsy/seizure [8A61-8A6Z]	[16]
Felbamate	DM1V5ZS	Moderate	Increased metabolism of Oxycodone caused by Felbamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[17]
Oxcarbazepine	DM5PU6O	Major	Increased metabolism of Oxycodone caused by Oxcarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[20]
Gabapentin	DM6T924	Major	Additive CNS depression effects by the combination of Oxycodone and Gabapentin.	Epilepsy/seizure [8A61-8A6Z]	[29]
Cenobamate	DM8KLU9	Major	Increased metabolism of Oxycodone caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[18]
Stiripentol	DMMSDOY	Major	Decreased metabolism of Oxycodone caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[20]
Fosphenytoin	DMOX3LB	Major	Increased metabolism of Oxycodone caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[20]
Clonazepam	DMTO13J	Major	Additive CNS depression effects by the combination of Oxycodone and Clonazepam.	Epilepsy/seizure [8A61-8A6Z]	[15]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Oxycodone caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[17]
Phenobarbital	DMXZOCG	Major	Increased metabolism of Oxycodone caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[16]
Carbamazepine	DMZOLBI	Major	Increased metabolism of Oxycodone caused by Carbamazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[20]
Eslicarbazepine	DMZREFQ	Major	Increased metabolism of Oxycodone caused by Eslicarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[20]
Dantrolene	DM1D8XY	Major	Additive CNS depression effects by the combination of Oxycodone and Dantrolene.	Fever [MG26]	[15]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Oxycodone caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[17]
Solifenacin	DMG592Q	Moderate	Additive CNS depression effects by the combination of Oxycodone and Solifenacin.	Functional bladder disorder [GC50]	[16]
Tolterodine	DMSHPW8	Moderate	Additive CNS depression effects by the combination of Oxycodone and Tolterodine.	Functional bladder disorder [GC50]	[16]
Itraconazole	DMCR1MV	Major	Decreased metabolism of Oxycodone caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[20]
Terbinafine	DMI6HUW	Moderate	Decreased metabolism of Oxycodone caused by Terbinafine mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[30]
Ketoconazole	DMPZI3Q	Major	Decreased metabolism of Oxycodone caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[20]
Propantheline	DM2EN6G	Moderate	Additive CNS depression effects by the combination of Oxycodone and Propantheline.	Gastric ulcer [DA60]	[16]
Cimetidine	DMH61ZB	Major	Decreased metabolism of Oxycodone caused by Cimetidine mediated inhibition of CYP450 enzyme.	Gastro-oesophageal reflux disease [DA22]	[20]
Sulfinpyrazone	DMEV954	Moderate	Increased metabolism of Oxycodone caused by Sulfinpyrazone mediated induction of CYP450 enzyme.	Gout [FA25]	[17]
Bumetanide	DMRV7H0	Moderate	Additive hypotensive effects by the combination of Oxycodone and Bumetanide.	Heart failure [BD10-BD1Z]	[31]
Boceprevir	DMBSHMF	Major	Decreased metabolism of Oxycodone caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[20]
Simeprevir	DMLUA9D	Moderate	Decreased metabolism of Oxycodone caused by Simeprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[20]
Telaprevir	DMMRV29	Major	Decreased metabolism of Oxycodone caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[20]
Isoniazid	DM5JVS3	Moderate	Decreased metabolism of Oxycodone caused by Isoniazid mediated inhibition of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[20]
Rifampin	DMA8J1G	Major	Increased metabolism of Oxycodone caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[27]
Rifapentine	DMCHV4I	Major	Increased metabolism of Oxycodone caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[18]
Delavirdine	DM3NF5G	Major	Decreased metabolism of Oxycodone caused by Delavirdine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Fosamprenavir	DM4W9B3	Major	Decreased metabolism of Oxycodone caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Cobicistat	DM6L4H2	Major	Decreased metabolism of Oxycodone caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Efavirenz	DMC0GSJ	Major	Increased metabolism of Oxycodone caused by Efavirenz mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[18]
Etravirine	DMGV8QU	Major	Increased metabolism of Oxycodone caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[18]
Amprenavir	DMLMXE0	Major	Decreased metabolism of Oxycodone caused by Amprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Darunavir	DMN3GCH	Major	Decreased metabolism of Oxycodone caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Atazanavir	DMSYRBX	Major	Decreased metabolism of Oxycodone caused by Atazanavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Ritonavir	DMU764S	Major	Decreased metabolism of Oxycodone caused by Ritonavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[32]
Verapamil	DMA7PEW	Major	Decreased metabolism of Oxycodone caused by Verapamil mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[20]
Conivaptan	DM1V329	Major	Decreased metabolism of Oxycodone caused by Conivaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[20]
Belladonna	DM2RBWK	Moderate	Additive antimotility effects by the combination of Oxycodone and Belladonna.	Infectious gastroenteritis/colitis [1A40]	[16]
Berotralstat	DMWA2DZ	Major	Decreased metabolism of Oxycodone caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[20]
Suvorexant	DM0E6S3	Major	Additive CNS depression effects by the combination of Oxycodone and Suvorexant.	Insomnia [7A00-7A0Z]	[15]
Amobarbital	DM0GQ8N	Major	Increased metabolism of Oxycodone caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[16]
Ramelteon	DM7IW9J	Major	Additive CNS depression effects by the combination of Oxycodone and Ramelteon.	Insomnia [7A00-7A0Z]	[15]
Flurazepam	DMAL4G0	Major	Additive CNS depression effects by the combination of Oxycodone and Flurazepam.	Insomnia [7A00-7A0Z]	[15]
Triazolam	DMETYK5	Major	Additive CNS depression effects by the combination of Oxycodone and Triazolam.	Insomnia [7A00-7A0Z]	[15]
Zaleplon	DMGFWSM	Major	Additive CNS depression effects by the combination of Oxycodone and Zaleplon.	Insomnia [7A00-7A0Z]	[15]
Propiomazine	DMKY8V1	Major	Additive CNS depression effects by the combination of Oxycodone and Propiomazine.	Insomnia [7A00-7A0Z]	[15]
Tasimelteon	DMLOQ1V	Major	Additive CNS depression effects by the combination of Oxycodone and Tasimelteon.	Insomnia [7A00-7A0Z]	[15]
Paraldehyde	DMOC1BX	Major	Additive CNS depression effects by the combination of Oxycodone and Paraldehyde.	Insomnia [7A00-7A0Z]	[15]
ITI-007	DMUQ1DO	Major	Additive CNS depression effects by the combination of Oxycodone and ITI-007.	Insomnia [7A00-7A0Z]	[15]
Quazepam	DMY4D87	Major	Additive CNS depression effects by the combination of Oxycodone and Quazepam.	Insomnia [7A00-7A0Z]	[15]
Estazolam	DMZGXUM	Major	Additive CNS depression effects by the combination of Oxycodone and Estazolam.	Insomnia [7A00-7A0Z]	[15]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of lowers seizure threshold by the combination of Oxycodone and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[33]
Clidinium	DMUMQZ0	Moderate	Additive antimotility effects by the combination of Oxycodone and Clidinium.	Irritable bowel syndrome [DD91]	[16]
Dicyclomine	DMZSDGX	Moderate	Additive antimotility effects by the combination of Oxycodone and Dicyclomine.	Irritable bowel syndrome [DD91]	[16]
Remimazolam	DMLVSYX	Major	Additive CNS depression effects by the combination of Oxycodone and Remimazolam.	Labour/delivery anaesthesia complication [JB0C]	[15]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Decreased metabolism of Oxycodone caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[19]
Crizotinib	DM4F29C	Major	Decreased metabolism of Oxycodone caused by Crizotinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[20]
Ceritinib	DMB920Z	Major	Decreased metabolism of Oxycodone caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[20]
PF-06463922	DMKM7EW	Major	Increased metabolism of Oxycodone caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[18]
Osimertinib	DMRJLAT	Moderate	Increased metabolism of Oxycodone caused by Osimertinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[19]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Oxycodone caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[20]
Lumefantrine	DM29GAD	Moderate	Decreased metabolism of Oxycodone caused by Lumefantrine mediated inhibition of CYP450 enzyme.	Malaria [1F40-1F45]	[20]
Idelalisib	DM602WT	Major	Decreased metabolism of Oxycodone caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[20]
IPI-145	DMWA24P	Major	Decreased metabolism of Oxycodone caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[20]
Blinatumomab	DMGECIJ	Moderate	Decreased metabolism of Oxycodone caused by Blinatumomab mediated inhibition of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[34]
Vemurafenib	DM62UG5	Moderate	Increased metabolism of Oxycodone caused by Vemurafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[17]
LGX818	DMNQXV8	Moderate	Increased metabolism of Oxycodone caused by LGX818 mediated induction of CYP450 enzyme.	Melanoma [2C30]	[35]
Dabrafenib	DMX6OE3	Major	Increased metabolism of Oxycodone caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[18]
Danazol	DML8KTN	Moderate	Decreased metabolism of Oxycodone caused by Danazol mediated inhibition of CYP450 enzyme.	Menstrual cycle bleeding disorder [GA20]	[20]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Oxycodone and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[36]
Almogran	DM7I64Z	Moderate	Additive serotonergic effects by the combination of Oxycodone and Almogran.	Migraine [8A80]	[23]
Frovatriptan	DM7RE8P	Moderate	Additive serotonergic effects by the combination of Oxycodone and Frovatriptan.	Migraine [8A80]	[23]
Rizatriptan	DMDJMA3	Moderate	Additive serotonergic effects by the combination of Oxycodone and Rizatriptan.	Migraine [8A80]	[23]
Naratriptan	DMO50U2	Moderate	Additive serotonergic effects by the combination of Oxycodone and Naratriptan.	Migraine [8A80]	[23]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Oxycodone and Lasmiditan.	Migraine [8A80]	[37]
Exjade	DMHPRWG	Moderate	Increased metabolism of Oxycodone caused by Exjade mediated induction of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[17]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Oxycodone and Flibanserin.	Mood disorder [6A60-6E23]	[38]
Thalidomide	DM70BU5	Moderate	Additive CNS depression effects by the combination of Oxycodone and Thalidomide.	Multiple myeloma [2A83]	[39]
Rifabutin	DM1YBHK	Major	Increased metabolism of Oxycodone caused by Rifabutin mediated induction of CYP450 enzyme.	Mycobacterium infection [1B10-1B21]	[18]
Fedratinib	DM4ZBK6	Major	Decreased metabolism of Oxycodone caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[20]
Nilotinib	DM7HXWT	Moderate	Decreased metabolism of Oxycodone caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[20]
Imatinib	DM7RJXL	Major	Decreased metabolism of Oxycodone caused by Imatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[20]
Prasugrel	DM7MT6E	Moderate	Altered absorption of Oxycodone due to GI dynamics variation caused by Prasugrel.	Myocardial infarction [BA41-BA43]	[40]
Modafinil	DMYILBE	Major	Increased metabolism of Oxycodone caused by Modafinil mediated induction of CYP450 enzyme.	Narcolepsy [7A20]	[18]
Netupitant	DMEKAYI	Major	Decreased metabolism of Oxycodone caused by Netupitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[20]
Metoclopramide	DMFA5MY	Moderate	Antagonize the effect of Oxycodone when combined with Metoclopramide.	Nausea/vomiting [MD90]	[41]
Granisetron	DMIUW25	Moderate	Additive serotonergic effects by the combination of Oxycodone and Granisetron.	Nausea/vomiting [MD90]	[23]
Dolasetron	DMMG26Z	Moderate	Additive serotonergic effects by the combination of Oxycodone and Dolasetron.	Nausea/vomiting [MD90]	[23]
Ondansetron	DMOTQ1I	Moderate	Additive serotonergic effects by the combination of Oxycodone and Ondansetron.	Nausea/vomiting [MD90]	[23]
Bupropion	DM5PCS7	Major	Increased risk of lowers seizure threshold by the combination of Oxycodone and Bupropion.	Nicotine use disorder [6C4A]	[42]
Sibutramine	DMFJTDI	Moderate	Additive serotonergic effects by the combination of Oxycodone and Sibutramine.	Obesity [5B80-5B81]	[23]
Dexfenfluramine	DMJ7YDS	Moderate	Additive serotonergic effects by the combination of Oxycodone and Dexfenfluramine.	Obesity [5B80-5B81]	[23]
Levomethadyl Acetate	DM06HG5	Major	Additive CNS depression effects by the combination of Oxycodone and Levomethadyl Acetate.	Opioid use disorder [6C43]	[21]
Apraclonidine	DMO4PVE	Moderate	Additive CNS depression effects by the combination of Oxycodone and Apraclonidine.	Optic nerve disorder [9C40]	[43]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Oxycodone caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[20]
Biperiden	DME78OA	Moderate	Additive CNS depression effects by the combination of Oxycodone and Biperiden.	Parkinsonism [8A00]	[44]
Pimavanserin	DMR7IVC	Major	Additive CNS depression effects by the combination of Oxycodone and Pimavanserin.	Parkinsonism [8A00]	[15]
Orphenadrine	DMW542E	Major	Additive CNS depression effects by the combination of Oxycodone and Orphenadrine.	Parkinsonism [8A00]	[15]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Oxycodone caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[45]
Methylscopolamine	DM5VWOB	Moderate	Additive CNS depression effects by the combination of Oxycodone and Methylscopolamine.	Peptic ulcer [DA61]	[16]
Lanreotide acetate	DMG6ZU4	Moderate	Decreased metabolism of Oxycodone caused by Lanreotide acetate mediated inhibition of CYP450 enzyme.	Pituitary gland disorder [5A60-5A61]	[20]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Oxycodone caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[46]
Lonafarnib	DMGM2Z6	Major	Decreased metabolism of Oxycodone caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[20]
ABIRATERONE	DM8V75C	Major	Decreased metabolism of Oxycodone caused by ABIRATERONE mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[20]
Ustekinumab	DMHTYK3	Moderate	Altered metabolism of Oxycodone due to Ustekinumab alters the formation of CYP450 enzymes.	Psoriasis [EA90]	[19]
Ixekizumab	DMXW92T	Moderate	Altered metabolism of Oxycodone due to Ixekizumab alters the formation of CYP450 enzymes.	Psoriasis [EA90]	[19]
Triflupromazine	DMKFQJP	Major	Additive CNS depression effects by the combination of Oxycodone and Triflupromazine.	Psychotic disorder [6A20-6A25]	[15]
Bosentan	DMIOGBU	Major	Increased metabolism of Oxycodone caused by Bosentan mediated induction of CYP450 enzyme.	Pulmonary hypertension [BB01]	[18]
Tocilizumab	DM7J6OR	Moderate	Altered metabolism of Oxycodone due to Tocilizumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[19]
Canakinumab	DM8HLO5	Moderate	Altered metabolism of Oxycodone due to Canakinumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[19]
Rilonacept	DMGLUQS	Moderate	Altered metabolism of Oxycodone due to Rilonacept alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[19]
Golimumab	DMHZV7X	Moderate	Altered metabolism of Oxycodone due to Golimumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[19]
Nafcillin	DMN9RPO	Major	Increased metabolism of Oxycodone caused by Nafcillin mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[18]
Sarilumab	DMOGNXY	Moderate	Altered metabolism of Oxycodone due to Sarilumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[19]
Mesoridazine	DM2ZGAN	Major	Additive CNS depression effects by the combination of Oxycodone and Mesoridazine.	Schizophrenia [6A20]	[47]
Thioridazine	DM35M8J	Major	Additive CNS depression effects by the combination of Oxycodone and Thioridazine.	Schizophrenia [6A20]	[15]
Aripiprazole	DM3NUMH	Major	Additive CNS depression effects by the combination of Oxycodone and Aripiprazole.	Schizophrenia [6A20]	[15]
Iloperidone	DM6AUFY	Major	Additive CNS depression effects by the combination of Oxycodone and Iloperidone.	Schizophrenia [6A20]	[15]
Paliperidone	DM7NPJS	Major	Additive CNS depression effects by the combination of Oxycodone and Paliperidone.	Schizophrenia [6A20]	[15]
Haloperidol	DM96SE0	Major	Additive CNS depression effects by the combination of Oxycodone and Haloperidol.	Schizophrenia [6A20]	[15]
Perphenazine	DMA4MRX	Major	Additive CNS depression effects by the combination of Oxycodone and Perphenazine.	Schizophrenia [6A20]	[15]
Molindone	DMAH70G	Major	Additive CNS depression effects by the combination of Oxycodone and Molindone.	Schizophrenia [6A20]	[15]
Thiothixene	DMDINC4	Major	Additive CNS depression effects by the combination of Oxycodone and Thiothixene.	Schizophrenia [6A20]	[47]
Trifluoperazine	DMKBYWI	Major	Additive CNS depression effects by the combination of Oxycodone and Trifluoperazine.	Schizophrenia [6A20]	[15]
Risperidone	DMN6DXL	Major	Additive CNS depression effects by the combination of Oxycodone and Risperidone.	Schizophrenia [6A20]	[15]
Asenapine	DMSQZE2	Major	Additive CNS depression effects by the combination of Oxycodone and Asenapine.	Schizophrenia [6A20]	[15]
Pimozide	DMW83TP	Major	Additive CNS depression effects by the combination of Oxycodone and Pimozide.	Schizophrenia [6A20]	[15]
Fentanyl	DM8WAHT	Major	Additive CNS depression effects by the combination of Oxycodone and Fentanyl.	Sensation disturbance [MB40]	[15]
Voxelotor	DMCS6M5	Major	Decreased metabolism of Oxycodone caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[20]
Telotristat ethyl	DMDIYFZ	Major	Increased metabolism of Oxycodone caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[27]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Oxycodone caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[20]
Armodafinil	DMGB035	Major	Increased metabolism of Oxycodone caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[18]
LEE011	DMMX75K	Major	Decreased metabolism of Oxycodone caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[20]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Oxycodone caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[48]
Brilinta	DMBR01X	Moderate	Altered absorption of Oxycodone due to GI dynamics variation caused by Brilinta.	Thrombosis [DB61-GB90]	[40]
Clopidogrel	DMOL54H	Moderate	Altered absorption of Oxycodone due to GI dynamics variation caused by Clopidogrel.	Thrombosis [DB61-GB90]	[40]
Tizanidine	DMR2IQ4	Major	Additive CNS depression effects by the combination of Oxycodone and Tizanidine.	Tonus and reflex abnormality [MB47]	[15]
Elagolix	DMB2C0E	Major	Increased metabolism of Oxycodone caused by Elagolix mediated induction of CYP450 enzyme.	Uterine fibroid [2E86]	[18]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
Butylated hydroxytoluene	E00336	31404	Antioxidant
D&C red no. 27	E00381	83511	Colorant
D&C red no. 30	E00456	3000709	Colorant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Isopropyl alcohol	E00070	3776	Antimicrobial preservative; Solvent
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Myristic acid	E00204	11005	Emulsifying agent; Penetration agent; lubricant
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Aluminum trihydroxide	E00505	10176082	Alkalizing agent; Vaccine adjuvant
Ammonia	E00007	222	Alkalizing agent
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Butyl alcohol	E00011	263	Flavoring agent; Solvent
Dibutyl sebacate	E00160	7986	Plasticizing agent
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Potassium hydroxide	E00233	14797	Alkalizing agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium alginate	E00671	Not Available	Binding agent; Disintegrant; Suspending agent; Viscosity-controlling agent
Sodium hydroxide	E00234	14798	Alkalizing agent
Sorbic acid	E00441	643460	Antimicrobial preservative
Stearyl alcohol	E00172	8221	Emollient; Emulsifying agent; Stiffening agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Water	E00035	962	Solvent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Oxycodone 15 mg tablet	15 mg	Abuse-Deterrent Oral Tablet	Oral
Oxycodone 30 mg tablet	30 mg	Abuse-Deterrent Oral Tablet	Oral
Oxycodone 5 mg tablet	5 mg	Abuse-Deterrent Oral Tablet	Oral
Oxycodone 80 mg tablet	80 mg	12 HR Extended Release Oral Tablet	Oral
Oxycodone 60 mg tablet	60 mg	12 HR Extended Release Oral Tablet	Oral
Oxycodone 80 mg tablet	80 mg	Abuse-Deterrent 12 HR Extended Release Oral Tablet	Oral
Oxycodone 5 mg capsule	5 mg	Oral Capsule	Oral
Oxycodone 30 mg tablet	30 mg	12 HR Extended Release Tablet	Oral
Oxycodone 30 mg tablet	30 mg	Abuse-Deterrent 12 HR Extended Release Oral Tablet	Oral
Oxycodone 60 mg tablet	60 mg	Abuse-Deterrent 12 HR Extended Release Oral Tablet	Oral
Oxycodone 60 mg tablet	60 mg	12 HR Extended Release Tablet	Oral
Oxycodone 20 mg tablet	20 mg	Abuse-Deterrent 12 HR Extended Release Oral Tablet	Oral
Oxycodone 20 mg tablet	20 mg	12 HR Extended Release Tablet	Oral
Oxycodone 40 mg tablet	40 mg	12 HR Extended Release Tablet	Oral
Oxycodone 80 mg tablet	80 mg	12 HR Extended Release Tablet	Oral
Oxycodone 15 mg tablet	15 mg	Abuse-Deterrent 12 HR Extended Release Oral Tablet	Oral
Oxycodone 13.5 mg capsule	13.5 mg	Abuse-Deterrent 12 HR Extended Release Oral Capsule	Oral
Oxycodone 18 mg capsule	18 mg	Abuse-Deterrent 12 HR Extended Release Oral Capsule	Oral
Oxycodone 27 mg capsule	27 mg	Abuse-Deterrent 12 HR Extended Release Oral Capsule	Oral
Oxycodone 36 mg capsule	36 mg	Abuse-Deterrent 12 HR Extended Release Oral Capsule	Oral
Oxycodone 9 mg capsule	9 mg	Abuse-Deterrent 12 HR Extended Release Oral Capsule	Oral
Oxycodone 15 mg tablet	15 mg	Oral Tablet	Oral
Oxycodone 20 mg tablet	20 mg	Oral Tablet	Oral
Oxycodone 10 mg tablet	10 mg	Abuse-Deterrent 12 HR Extended Release Oral Tablet	Oral
Oxycodone 10 mg tablet	10 mg	12 HR Extended Release Tablet	Oral
Oxycodone 30 mg tablet	30 mg	Oral Tablet	Oral
Oxycodone 10 mg tablet	10 mg	Oral Tablet	Oral
Oxycodone 5 mg tablet	5 mg	Oral Tablet	Oral
Oxycodone 20 mg tablet	20 mg	12 HR Extended Release Oral Tablet	Oral
Oxycodone 40 mg tablet	40 mg	12 HR Extended Release Oral Tablet	Oral
Oxycodone 40 mg tablet	40 mg	Abuse-Deterrent 12 HR Extended Release Oral Tablet	Oral
Oxycodone 10 mg tablet	10 mg	12 HR Extended Release Oral Tablet	Oral
Oxycodone 15 mg tablet	15 mg	12 HR Extended Release Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] Oxycodone FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7093).
• [3] ClinicalTrials.gov (NCT01427283) A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain. U.S. National Institutes of Health.
• [4] BDDCS applied to over 900 drugs
• [5] Metabolism and Disposition of Prescription Opioids: A Review. Forensic Sci Rev. 2015 Jul;27(2):115-45.
• [6] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [7] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [8] Oxycodone: a pharmacological and clinical review. Clin Transl Oncol. 2007 May;9(5):298-307.
• [9] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319).
• [10] Chronic oxycodone induces integrated stress response in rat brain. BMC Neurosci. 2015 Sep 16;16:58. doi: 10.1186/s12868-015-0197-8.
• [11] Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety. Br J Pharmacol. 2010 Jun;160(4):919-30. doi: 10.1111/j.1476-5381.2010.00709.x.
• [12] Evaluation of Recombinant CYP3A4 Variants on the Metabolism of Oxycodone In Vitro. Chem Res Toxicol. 2021 Jan 18;34(1):103-109. doi: 10.1021/acs.chemrestox.0c00361. Epub 2021 Jan 4.
• [13] Product Information. Buprenex (buprenorphine). Reckitt and Colman Pharmaceutical, Richmond, VA.
• [14] Hansen BS, Dam M, Brandt J, et al "Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man." Acta Neurol Scand 61 (1980): 357-67. [PMID: 6998251]
• [15] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
• [16] Product Information. Apadaz (acetaminophen-benzhydrocodone). KemPharm, Inc, Coralville, IA.
• [17] Altice FL, Friedland GH, Cooney EL "Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone." AIDS 13 (1999): 957-62. [PMID: 10371177]
• [18] Canadian Pharmacists Association.
• [19] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [20] Cerner Multum, Inc. "Australian Product Information.".
• [21] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
• [22] Liu S-J, Wang RI "Case report of barbiturate-induced enhancement of methadone metabolism and withdrawal syndrome." Am J Psychiatry 141 (1984): 1287-8. [PMID: 6486271]
• [23] Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
• [24] Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
• [25] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
• [26] Gill SS, Wright EM, Reilly CS "Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study." Br J Anaesth 65 (1990): 760-5. [PMID: 2265045]
• [27] Product Information. Mycobutin (rifabutin). Pharmacia and Upjohn, Kalamazoo, MI.
• [28] Sturner WQ, Garriott JC "Deaths involving propoxyphene: a study of 41 cases over a two-year period." JAMA 223 (1973): 1125-30. [PMID: 4739371]
• [29] Eckhardt K, Ammon S, Hofmann U, Riebe A, Gugeler N, Mikus G "Gabapentin enhances the analgesic effect of morphine in healthy volunteers." Anesth Analg 91 (2000): 185-91. [PMID: 10866910]
• [30] AbdelRahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL "Investigation of terbinafine as a CYP2D6 inhibitor in vivo." Clin Pharmacol Ther 65 (1999): 465-72. [PMID: 10340911]
• [31] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595. [PMID: 9518913]
• [32] Lalovic B, Phillips B, Risler LL, Howald W, Shen DD "Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes." Drug Metab Dispos 32 (2004): 447-54. [PMID: 15039299]
• [33] Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
• [34] Product Information. Blincyto (blinatumomab). Amgen USA, Thousand Oaks, CA.
• [35] Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
• [36] Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
• [37] Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
• [38] Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
• [39] Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
• [40] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
• [41] Product Information. Reglan (metoclopramide). Wyeth-Ayerst Laboratories, Philadelphia, PA.
• [42] Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
• [43] Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
• [44] Product Information. Artane (trihexyphenidyl). Lederle Laboratories, Wayne, NJ.
• [45] Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
• [46] Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
• [47] Cerner Multum, Inc. "Canadian Product Information.".
• [48] Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.